At the end of FY2023 Q3 on September 30 2023, REGENXBIO INC ($NASDAQ:RGNX) had total revenue of USD 28.9 million, which was a 9.1% increase from the same period the year prior. Net income for the quarter was USD -61.9 million, a decrease of -75.5 million from the previous year.
GoodWhale has provided an assessment of REGENXBIO INC‘s financials, according to the Star Chart REGENXBIO INC is strong in asset and profitability, but medium in growth and weak in dividend. Additionally, REGENXBIO INC has an intermediate health score of 4/10 with regard to its cashflows and debt, meaning it may be able to sustain future operations in times of crisis. As REGENXBIO INC is classified as an ‘elephant’, a type of company rich in assets after deducting off liabilities, investors may be interested in such a company. Investors who are looking for a company with strong assets and profitability may find REGENXBIO INC to be an attractive option. Additionally, those looking for a company with the ability to sustain itself in times of financial hardship may also find REGENXBIO INC worth considering. In conclusion, given the factors mentioned above, REGENXBIO INC may be an attractive option for investors looking for a company with a strong asset base and profitability, as well as the ability to survive challenging financial times. More…
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Regenxbio Inc. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Regenxbio Inc. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Regenxbio Inc. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Regenxbio Inc are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The company’s lead product candidate, RGX-111, is in clinical trials for the treatment of homozygous familial dysautonomia, a rare genetic disease. Regenxbio’s competitors include Adverum Biotechnologies Inc, Novartis AG, and AbbVie Inc.
– Adverum Biotechnologies Inc ($NASDAQ:ADVM)
Adverum Biotechnologies Inc is a clinical-stage biotechnology company that specializes in the development of gene therapies. The company’s market cap as of 2022 is 81.27M and its ROE is -36.78%. The company’s goal is to develop gene therapies to treat serious and rare diseases.
Novartis AG is a global healthcare company that researches, develops, and markets a wide variety of health products, including over-the-counter and prescription drugs, vaccines, and consumer health products. The company has a market capitalization of 174.68 billion as of 2022 and a return on equity of 24.65%. Novartis is headquartered in Basel, Switzerland, and has operations in over 140 countries.
AbbVie Inc is a pharmaceutical company with a market cap of 255.35B as of 2022. The company has a Return on Equity of 66.07%. AbbVie Inc produces a variety of pharmaceutical products and focuses on research and development in order to bring new and innovative treatments to patients. The company’s products are used to treat a wide range of conditions, including cancer, HIV/AIDS, and Alzheimer’s disease. AbbVie Inc is committed to improving the lives of patients and their families by providing quality products and services.
REGENXBIO INC reported total revenue of USD 28.9 million for the end of FY2023 Q3, an increase of 9.1% from the previous year. For potential investors, this is a mixed message given the increased revenue but decreased profits. It is important to research more closely and take into account the company’s long-term profitability, competitive landscape, financial health, and other factors before investing in REGENXBIO INC.